Chemerin As A Non-Invasive Serum Marker for Non-Alcoholic Fatty Liver Disease
Mohamed, G., Salama, M., Byoumy, E., Mohamed, A., Ibrahim, W., El-shafie, A., Abdallah, M. (2021). Chemerin As A Non-Invasive Serum Marker for Non-Alcoholic Fatty Liver Disease. EKB Journal Management System, 84(1), 1786-1790. doi: 10.21608/ejhm.2021.177253
Ghada Mohamed; Mohamed M Salama; Essam Byoumy; Azza Mohamed; Wesam Ibrahim; Ahmed El-shafie; Mohamed Abdallah. "Chemerin As A Non-Invasive Serum Marker for Non-Alcoholic Fatty Liver Disease". EKB Journal Management System, 84, 1, 2021, 1786-1790. doi: 10.21608/ejhm.2021.177253
Mohamed, G., Salama, M., Byoumy, E., Mohamed, A., Ibrahim, W., El-shafie, A., Abdallah, M. (2021). 'Chemerin As A Non-Invasive Serum Marker for Non-Alcoholic Fatty Liver Disease', EKB Journal Management System, 84(1), pp. 1786-1790. doi: 10.21608/ejhm.2021.177253
Mohamed, G., Salama, M., Byoumy, E., Mohamed, A., Ibrahim, W., El-shafie, A., Abdallah, M. Chemerin As A Non-Invasive Serum Marker for Non-Alcoholic Fatty Liver Disease. EKB Journal Management System, 2021; 84(1): 1786-1790. doi: 10.21608/ejhm.2021.177253

Chemerin As A Non-Invasive Serum Marker for Non-Alcoholic Fatty Liver Disease

The Egyptian Journal of Hospital Medicine
Article 24, Volume 84, Issue 1, July 2021, Page 1786-1790  XML PDF (340.29 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2021.177253
View on SCiNiTO View on SCiNiTO
Authors
Ghada Mohamedorcid 1; Mohamed M Salama2; Essam Byoumy2; Azza Mohamed2; Wesam Ibrahim2; Ahmed El-shafie2; Mohamed Abdallah2
1Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
2Ghada Abdelrahman Mohamed, Gastroenterology and Hepatology Unit, Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo
Abstract
Background: Attempts have been made to recognize noninvasive markers for the identification of non-alcoholic fatty liver disease (NAFLD). Chemerin is a newly defined adipokine linked to insulin resistance and adipogenesis.
Objective: This study intended to evaluate the diagnostic ability of serum chemerin compared with NAFLD fibrosis score as a noninvasive marker for the diagnosis and grading of NAFLD.
Patients and methods: We enrolled 60 NAFLD patients and categorized them into 3 subgroups based on the fatty liver grade by ultrasound. Thirty healthy participants were recruited as a control group. ELISA method was used for serum chemerin levels measurement. Results: Serum chemerin levels were significantly higher in NAFLD cases than controls (p ≤ 0.001). Furthermore, these levels were positively correlated with the fatty liver grade (p ≤ 0.001). Serum chemerin was comparable to NAFLD fibrosis score as regards NAFLD diagnosis (p ≤ 0.001). Patients within the gray zone of NAFLD fibrosis score had a significantly higher serum chemerin levels in comparison to patients under the gray zone (p ≤ 0.001).
Conclusion: Serum chemerin is a promising marker for diagnosing and grading of NAFLD. More research is required to determine its definitive clinical benefit in patients with NAFLD.
 
Keywords
Non-alcoholic fatty liver disease; Chemerin; Adipokines; Obesity; NAFLD fibrosis score
Statistics
Article View: 280
PDF Download: 500